TLR-AD1

N/A

Report date: 2022/11/04 13:33:01

Base Information

Drug NameTLR-AD1
Drug Alias Namea tumor lysate-pulsed dendritic cell vaccine, enhanced by addition of a TLR 2, 4, 9 ligand adjuvant cocktail (Pam3cys, LPS, CpG ODN)
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Dendritic cell vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsBrain Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNovAccess Global Inc
China Registration ClassN/A

Develop Information

Active CompaniesNovAccess Global Inc
Inactive CompaniesN/A
Active IndicationsBrain Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A